I Innate Pharma SA
I
Fermé
1.728 5.88
Résumé
Variation du prix de l'action
24h
Min
1.63
Max
2.165
Revenu | -6.5M -28M |
|---|---|
Ventes | -6.9M -2.1M |
BPA | -0.12 |
Marge bénéficiaire | 1,342.644 |
Employés | 163 |
EBITDA | -5.9M -31M |
Capitalisation Boursière | 8.7M 118M |
|---|---|
Ouverture précédente | -4.15 |
Clôture précédente | 1.728 |
Score Technique
By Trading Central
Confiance
Weak Bullish Evidence
Innate Pharma SA Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Innate Pharma SA prévision
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos Innate Pharma SA
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
